NCT04701060View on ClinicalTrials.gov

Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 26, 2021

Primary Completion Date

March 4, 2024

Study Completion Date

October 4, 2024

Conditions
Resectable Hepatocellular Carcinoma
Interventions
DRUG

Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w

preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year

Trial Locations (1)

300060

Tianjin Medical University Cancer Insititute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT04701060 - Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter